Vizgen is a privately held biotech company developing the next generation of spatially resolved, single-cell transcriptomics technology and toolbox. The company's patented MERFISH (multiplexed error-robust fluorescence in situ hybridization) technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. The high throughput and resolution and the low cost per cell achieved by the technology will enable a wide range of tissue-scale basic research and development and will be instrumental to efforts to discover and map cell types and states in a range of tissues and organisms. Tools employing MERFISH will advance data-driven drug discovery and development and enable new insights for clinical pathology and diagnostics.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
2019
Founded
Investors
0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
When was Vizgen founded?
Vizgen was founded in 2019.
What industry is Vizgen in?
Vizgen operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Vizgen based?
Vizgen is headquartered in Cambridge, United States.
Find investors for your startup like Vizgen
Gritt sends AI-personalised outreach to each investor — from your Gmail